FATE THERAPEUTICS INC Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
FATE THERAPEUTICS INC (FATE) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $42.48 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $42.48M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $49.62M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $56.85M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $50.85M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations |
|---|---|
| 2026-06-30 | $42.48M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $49.62M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $56.85M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $50.85M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $51.48M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $55.15M 10-Q · filed 2026-05-13 |
| 2024-12-31 | $46.28M 10-Q · filed 2026-08-13 |
| 2024-09-30 | $48.14M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $52.09M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $136.50M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $57.05M 10-K · filed 2026-02-26 |
| 2023-09-30 | $48.51M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $61.98M 10-Q · filed 2024-08-13 |
| 2023-03-31 | $57.25M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $76.56M 10-K · filed 2025-03-05 |
| 2022-09-30 | $97.32M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $70.50M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $79.97M 10-Q · filed 2023-05-03 |
| 2021-12-31 | $148.81M 10-K · filed 2024-02-26 |
| 2021-09-30 | $144.41M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $91.88M 10-Q · filed 2022-08-03 |
| 2021-03-31 | $121.64M 10-Q · filed 2022-05-04 |
| 2020-12-31 | $182.57M 10-K · filed 2023-02-28 |
| 2020-09-30 | $364.36M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $448.30M 10-Q · filed 2021-08-04 |
| 2020-03-31 | $98.59M 10-Q · filed 2021-05-05 |
| 2019-12-31 | $100.04M 10-K · filed 2023-02-28 |
| 2019-09-30 | $249.81M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $71.66M 10-Q · filed 2020-08-05 |
| 2019-03-31 | $183.26M 10-Q · filed 2020-05-11 |
| 2018-12-31 | $190.74M 10-K · filed 2022-02-28 |
| 2018-09-30 | $183.47M 10-Q · filed 2019-11-05 |
| 2018-06-30 | $36.39M 10-Q · filed 2019-08-06 |
| 2018-03-31 | $33.03M 10-Q · filed 2019-05-07 |
| 2017-12-31 | $89.07M 10-K · filed 2021-02-24 |
| 2017-09-30 | $43.35M 10-Q · filed 2018-11-01 |
| 2017-06-30 | $31.18M 10-Q · filed 2018-08-06 |
| 2016-12-31 | $88.73M 10-K · filed 2020-03-02 |
| 2015-12-31 | $64.93M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |